Inhibition of adenovirus transport from the endosome to the cell nucleus by rotenone.

adenovirus infection antiviral compound cytomegalovirus microtubular polymerization rotenoids

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2023
Historique:
received: 12 09 2023
accepted: 27 12 2023
medline: 26 1 2024
pubmed: 26 1 2024
entrez: 26 1 2024
Statut: epublish

Résumé

Regardless of the clinical impact of human adenovirus (HAdV) infections in the healthy population and its high morbidity in immunosuppressed patients, a specific treatment is still not yet available. In this study, we screened the CM1407 COST Action's chemical library, comprising 1,233 natural products to identify compounds that restrict HAdV infection. Among them, we identified rotenolone, a compound that significantly inhibited HAdV infection. Next, we selected four isoflavonoid-type compounds (e.g., rotenone, deguelin, millettone, and tephrosin), namely rotenoids, structurally related to rotenolone in order to evaluate and characterized

Identifiants

pubmed: 38273842
doi: 10.3389/fphar.2023.1293296
pii: 1293296
pmc: PMC10808720
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1293296

Informations de copyright

Copyright © 2024 Balsera-Manzanero, Ghirga, Ruiz-Molina, Mori, Pachón, Botta, Cordero, Quaglio and Sánchez-Céspedes.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

María Balsera-Manzanero (M)

Unidad Clínica de Enfermedades Infecciosas, Microbiología y Parasitología, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.

Francesca Ghirga (F)

Department of Chemistry and Technology of Drugs, Sapienza University of Rome, Rome, Italy.

Ana Ruiz-Molina (A)

Unidad Clínica de Enfermedades Infecciosas, Microbiología y Parasitología, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.

Mattia Mori (M)

Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.

Jerónimo Pachón (J)

Instituto de Biomedicina de Sevilla (IBiS), Hospitales Universitarios Virgen del Rocío y Virgen Macarena/CSIC/Universidad de Sevilla, Sevilla, Spain.
Departamento de Medicina, Facultad de Medicina, Universidad de Sevilla, Sevilla, Spain.

Bruno Botta (B)

Department of Chemistry and Technology of Drugs, Sapienza University of Rome, Rome, Italy.

Elisa Cordero (E)

Unidad Clínica de Enfermedades Infecciosas, Microbiología y Parasitología, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
Departamento de Medicina, Facultad de Medicina, Universidad de Sevilla, Sevilla, Spain.
CIBERINFEC, ISCIII-CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.

Deborah Quaglio (D)

Department of Chemistry and Technology of Drugs, Sapienza University of Rome, Rome, Italy.

Javier Sánchez-Céspedes (J)

Unidad Clínica de Enfermedades Infecciosas, Microbiología y Parasitología, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
CIBERINFEC, ISCIII-CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.

Classifications MeSH